| 1 |
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Roland Baron, Georges Rawadi · Endocrinology
|
30 Mar 2007 |
587 |
| 2 |
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases
Open access |
19 Mar 2021 |
359 |
| 3 |
Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents
H‐S Lin, Ching Yuan Hu, H‐Y Chan et al. · British Journal of Pharmacology
Open access |
26 Feb 2007 |
275 |
| 4 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine
Open access |
20 May 2018 |
238 |
| 5 |
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology
Open access |
5 Sep 2013 |
237 |
| 6 |
Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Yingshe Zhao, Richard Bachelier, Isabelle Treilleux et al. · Cancer Research
|
15 Jun 2007 |
211 |
| 7 |
A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
Suzanne J. F. Kaptein et al. · Nature
Open access |
6 Oct 2021 |
202 |
| 8 |
Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis
Nicolas Desroy et al. · Journal of Medicinal Chemistry
Open access |
17 Apr 2017 |
141 |
| 9 |
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
Toby M. Maher et al. · JAMA
Open access252 authors |
9 May 2023 |
140 |
| 10 |
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Florence Namour, Paul M. Diderichsen, Eugene H. Cox et al. · Clinical Pharmacokinetics
Open access |
13 Feb 2015 |
138 |
| 11 |
Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates
Olivia Goethals et al. · Nature
Open access |
15 Mar 2023 |
136 |
| 12 |
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Christel J. Menet, Stephen Robert Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry
Open access |
4 Nov 2014 |
124 |
| 13 |
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
Nick Vandeghinste, Jürgen Klattig, Catherine Jagerschmidt et al. · Journal of Investigative Dermatology
Open access |
21 Feb 2018 |
118 |
| 14 |
The Hedgehog Receptor Patched Is Involved in Cholesterol Transport
Michel Bidet, Olivier Joubert, Benoı̂t Lacombe et al. · PLoS ONE
Open access |
8 Sep 2011 |
117 |
| 15 |
Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic
Mathieu Pizzonero et al. · Journal of Medicinal Chemistry
Open access |
7 Nov 2014 |
114 |
| 16 |
Targeted Disruption of the Wnt Regulator Kremen Induces Limb Defects and High Bone Density
Kristina Ellwanger, Hiroaki Saito, Philippe Clément-Lacroix et al. · Molecular and Cellular Biology
Open access |
28 May 2008 |
108 |
| 17 |
Targeting of αv-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer
Geertje van der Horst, Christel van den Hoogen, Jeroen T. Buijs et al. · Neoplasia
Open access |
Jun 2011 |
108 |
| 18 |
The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
Tobias Puengel, Steve De Vos, Jana Hundertmark et al. · Journal of Clinical Medicine
Open access |
16 Apr 2020 |
87 |
| 19 |
Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis
Niklas Jonathan Lang et al. · Science Translational Medicine
|
6 Dec 2023 |
85 |
| 20 |
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Frédéric P. Vanhoutte, Minodora Mazur, O.I. Voloshyn et al. · Arthritis & Rheumatology
Open access |
16 Jun 2017 |
82 |
| 21 |
Discovery of Diarylhydantoins as New Selective Androgen Receptor Modulators
François Nique, Séverine Hebbe, Christophe Peixoto et al. · Journal of Medicinal Chemistry
Open access |
16 Aug 2012 |
79 |
| 22 |
Advances in the Discovery of Selective JAK Inhibitors
Christel J. Menet, Luc Van Rompaey, Raphaël Geney · Progress in medicinal chemistry
Book chapter |
2013 |
78 |
| 23 |
No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions
Petrine Wellendorph, Lars Dan Johansen, Anders A. Jensen et al. · Journal of Molecular Endocrinology
Open access |
22 Dec 2008 |
73 |
| 24 |
Envisioning the Future of European Food Systems: Approaches and Research Priorities After COVID-19
Matteo Vittuari et al. · Frontiers in Sustainable Food Systems
Open access |
9 Mar 2021 |
65 |
| 25 |
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric P. Vanhoutte et al. · Investigational New Drugs
Open access |
19 Jan 2016 |
65 |
| 26 |
Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors
Agnès Joncour et al. · Journal of Medicinal Chemistry
Open access |
21 Jul 2017 |
63 |
| 27 |
BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β3 expression
Hildegonda P. H. Naber, Eliza Wiercinska, Evangelia Pardali et al. · Cellular Oncology
Open access |
20 Sep 2011 |
62 |
| 28 |
Filgotinib: A Clinical Pharmacology Review
Florence Namour, Kacey Anderson, Cara Nelson et al. · Clinical Pharmacokinetics
Open access |
31 May 2022 |
60 |
| 29 |
Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis
F. Brebion et al. · Journal of Medicinal Chemistry
Open access |
15 Mar 2021 |
60 |
| 30 |
Discovery ofN-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent
Steven E. Van der Plas, Hans Kelgtermans, Tom De Munck et al. · Journal of Medicinal Chemistry
Open access |
17 Nov 2017 |
59 |
| 31 |
Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods
Denis Bucher, Pieter F. W. Stouten, Nicolas Triballeau · Journal of Chemical Information and Modeling
|
28 Feb 2018 |
58 |
| 32 |
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
Florence Namour, René Galien, Tim Van Kaem et al. · British Journal of Clinical Pharmacology
Open access |
8 Feb 2016 |
57 |
| 33 |
Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models
Yihao Li, Yvette Drabsch, Philippe Pujuguet et al. · Breast Cancer Research
Open access |
24 Feb 2015 |
57 |
| 34 |
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
Florence Namour, Julie Desrivot, Annegret Van der Aa et al. · Drug Metabolism Letters
|
12 Feb 2016 |
56 |
| 35 |
Adenomatous polyposis coli-mediated control of β-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors
Razvan L. Miclea, Marcel Karperien, Cathy A.J. Bosch et al. · BMC Developmental Biology
Open access |
8 Apr 2009 |
56 |
| 36 |
GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy
Anna Cozzoli, Roberta Francesca Capogrosso, Valeriana Teresa Sblendorio et al. · Pharmacological Research
|
22 Mar 2013 |
56 |
| 37 |
Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Xiaoyun Tang, Melinda Wuest, Matthew G.K. Benesch et al. · Molecular Cancer Therapeutics
|
23 Sep 2019 |
54 |
| 38 |
Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator
François Nique, Séverine Hebbe, Nicolas Triballeau et al. · Journal of Medicinal Chemistry
|
10 Sep 2012 |
53 |
| 39 |
IL‐17C amplifies epithelial inflammation in human psoriasis and atopic eczema
Felix Lauffer, Manja Jargosch, Veronika Baghin et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
2 Dec 2019 |
52 |
| 40 |
Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84
Zobaer Al Mahmud, Laura Jenkins, Trond Ulven et al. · Scientific Reports
Open access |
14 Dec 2017 |
50 |
| 41 |
Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy‐induced bone loss in vivo
Aymen I. Idris, Maala Krishnan, Petra Šimić et al. · The FASEB Journal
|
20 Jul 2010 |
49 |
| 42 |
Discovery of 9-Cyclopropylethynyl-2-(( S )-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1- a ]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial
Frédéric Labéguère et al. · Journal of Medicinal Chemistry
Open access |
9 Sep 2020 |
48 |
| 43 |
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
Stéphanie Lavazais, Manja Jargosch, Sonia Dupont et al. · Science Translational Medicine
|
15 Feb 2023 |
44 |
| 44 |
Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
Gert De Wilde, Maarten Gees, Sara Musch et al. · Frontiers in Pharmacology
Open access |
9 May 2019 |
42 |
| 45 |
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
Ellen van der Aar, Julie Desrivot, Sonia Dupont et al. · The Journal of Clinical Pharmacology
Open access |
23 Apr 2019 |
42 |
| 46 |
Targeting of Alpha-V Integrins Reduces Malignancy of Bladder Carcinoma
Geertje van der Horst, Lieke Bos, Maaike van der Mark et al. · PLoS ONE
Open access |
23 Sep 2014 |
42 |
| 47 |
Hydrogen sulphide‐releasing diclofenac derivatives inhibit breast cancer‐induced osteoclastogenesis in vitro and prevent osteolysis ex vivo
Joseph Frantzias, John G. Logan, Patrick Mollat et al. · British Journal of Pharmacology
Open access |
28 Sep 2011 |
42 |
| 48 |
Autotaxin facilitates selective LPA receptor signaling
Fernando Salgado-Polo, Razvan Borza, Minos–Timotheos Matsoukas et al. · Cell chemical biology
Open access |
2023 |
41 |
| 49 |
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
Jacqueline M. Tarrant, René Galien, Wanying Li et al. · Rheumatology and Therapy
Open access |
7 Jan 2020 |
37 |
| 50 |
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells
Francesca Megiorni et al. · Journal of Hematology & Oncology
Open access |
6 Oct 2017 |
37 |